These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35739635)

  • 1. Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
    Micieli A; Singh N; Jahn B; Siebert U; Menon BK; Demchuk AM
    Int J Stroke; 2023 Apr; 18(4):416-425. PubMed ID: 35739635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor Aspirin vs Clopidogrel Aspirin in
    Wang A; Meng X; Tian X; Zuo Y; Bath PM; Li H; Xie X; Jing J; Lin J; Wang Y; Zhao X; Liu L; Li Z; Jiang Y; Xu J; Wang F; Chen W; Cao M; Li J; Wang Y
    Neurology; 2023 Jan; 100(5):e497-e504. PubMed ID: 36535779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack.
    Narasimhalu K; Chan J; Ang YK; De Silva DA; Tan KB
    Int J Stroke; 2024 Feb; 19(2):209-216. PubMed ID: 37679898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
    Pan Y; Meng X; Jin A; Johnston SC; Li H; Bath PM; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Yang H; Cheng J; Wang Z; Wang Y
    JAMA Neurol; 2022 Aug; 79(8):739-745. PubMed ID: 35727586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.
    Zhang Z; Bao Y; Gu Y; Zhang M; Li X
    Br J Clin Pharmacol; 2024 Feb; 90(2):483-492. PubMed ID: 37795861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of
    Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
    Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
    Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
    Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
    JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
    Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
    J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
    Narasimhalu K; Ang YK; Tan DSY; De Silva DA; Tan KB
    Clin Drug Investig; 2020 Nov; 40(11):1063-1070. PubMed ID: 32959334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in
    Meng X; Wang A; Tian X; Johnston C; Li H; Bath PM; Xu Q; Zhang Y; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Wang Y
    Neurology; 2024 Feb; 102(3):e207809. PubMed ID: 38181311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by
    Zhou M; Chen W; Pan Y; Lin Y; Meng X; Zhao X; Liu L; Lin J; Li H; Wang Y; Wang Y
    Aging (Albany NY); 2020 Dec; 13(3):3994-4006. PubMed ID: 33411687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.
    Carroll J; Lopez Manzano C; Tomlinson E; Sadek A; Cooper C; Jones HE; Rowsell L; Knight J; Mumford A; Palmer R; Hollingworth W; Welton NJ; Whiting P
    Health Technol Assess; 2024 Sep; 28(57):1-194. PubMed ID: 39269241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction.
    Liu H; Jing J; Wang A; Xu Q; Meng X; Li H; Li Z; Wang Y
    Neurology; 2023 Apr; 100(16):e1643-e1654. PubMed ID: 36697242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
    JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor versus Clopidogrel in
    Wang Y; Meng X; Wang A; Xie X; Pan Y; Johnston SC; Li H; Bath PM; Dong Q; Xu A; Jing J; Lin J; Niu S; Wang Y; Zhao X; Li Z; Jiang Y; Li W; Liu L; Xu J; Chang L; Wang L; Zhuang X; Zhao J; Feng Y; Man H; Li G; Wang B;
    N Engl J Med; 2021 Dec; 385(27):2520-2530. PubMed ID: 34708996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.